6533b86dfe1ef96bd12ca00f
RESEARCH PRODUCT
Gender Differences in the Presentation and Outcomes of Hospitalized Patients With COVID-19
Charbel Maroun EidMartino PepeRodolfo RomeroFederico GuerraFabrizio UgoAlex F Castro-mejíaGisela FeltesAitor UribarriAdelina GonzalezJia HuangEnrico CerratoSergio Raposeiras RoubínVicente EstradaCarloalberto BiolèMatteo BiancoInmaculada Fernández-rozasVíctor Manuel Becerra-muñozNatividad Blasco-anguloMarcos García AguadoEmilio Alfonso-rodríguezAmanda SpiritoCarlos MacayaIbrahim AkinCristina Fernández-pérezIván J. Núñez-gilMaría C Viana-llamassubject
Malemedicine.medical_specialtyLeadership and ManagementAnosmiaComorbidityAssessment and DiagnosisCohort Studies03 medical and health sciencesSex Factors0302 clinical medicineHyposmiaInternal medicinemedicineHumans030212 general & internal medicine030223 otorhinolaryngologyCare PlanningAgedAged 80 and overbusiness.industryHealth PolicyCOVID-19General MedicineMiddle Agedmedicine.diseaseComorbidityHospitalizationSystemic inflammatory response syndromeHeart Disease Risk FactorsPropensity score matchingDisease ProgressionVomitingFemaleFundamentals and skillsmedicine.symptomLymphocytopeniabusinessCohort studydescription
Gender-related differences in COVID-19 clinical presentation, disease progression, and mortality have not been adequately explored. We analyzed the clinical profile, presentation, treatments, and outcomes of patients according to gender in the HOPE-COVID-19 International Registry. Among 2,798 enrolled patients, 1,111 were women (39.7%). Male patients had a higher prevalence of cardiovascular risk factors and more comorbidities at baseline. After propensity score matching, 876 men and 876 women were selected. Male patients more often reported fever, whereas female patients more often reported vomiting, diarrhea, and hyposmia/anosmia. Laboratory tests in men presented alterations consistent with a more severe COVID-19 infection (eg, significantly higher C-reactive protein, troponin, transaminases, lymphocytopenia, thrombocytopenia, and ferritin). Systemic inflammatory response syndrome, bilateral pneumonia, respiratory insufficiency, and renal failure were significantly more frequent in men. Men more often required pronation, corticosteroids, and tocilizumab administration. A significantly higher 30-day mortality was observed in men vs women (23.4% vs 19.2%; P = .039). Trial Numbers: NCT04334291/EUPAS34399.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-01 | Journal of Hospital Medicine |